- Our Pipeline - Kezar Life Sciences Inc.
4000 Shoreline Court Suite 300 South San Francisco, CA 94080 contact@kezarbio com (650) 822-5600 Visit us on LinkedIn
- Our Company - Kezar Life Sciences Inc.
At Kezar Life Sciences, we are developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins
- Investors Media - Kezar Life Sciences, Inc.
At Kezar Life Sciences, we are developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins
- Selective Immuno-proteasome Inhibition - Kezar Life Sciences Inc.
Unlike other therapeutic options that target a single type of immune cell or cytokine, zetomipzomib (KZR-616), Kezar’s first-in-class, selective immunoproteasome inhibitor, is designed to modulate many elements of the immune system when it is dysregulated without direct immunosuppression
- Executive Team - Kezar Life Sciences Inc.
John Fowler is our Co-Founder and a member of the board of directors He served as Chief Executive Officer of Kezar from June 2015 to November 2023 Prior to Kezar, between 2009 and 2014 John co-founded and was CEO of HealthCPA, a provider of patient advocacy and insurance navigation services
- Kezar Life Sciences Announces Positive Topline Results from the PORTOLA . . .
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2a clinical trial for autoimmune hepatitis
- Press Releases - Kezar Life Sciences, Inc.
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
- Kezar Life Sciences to Present Topline Results from the PORTOLA Phase . . .
The event will highlight topline data from Kezar’s PORTOLA trial, a placebo-controlled, randomized, double-blind Phase 2a clinical trial evaluating the efficacy and safety of zetomipzomib in patients with AIH
|